Consistent with this notion, we also found (i) that cancer patients with bone metastasis had higher plasma CGRP levels compared to those without bone metastasis, (ii) that samples from bone metastatic tumors expressed higher levels of CRLR compared with those from other metastases, primary tumors, or benign tissues, and (iii) that CRLR expression in tumor negatively correlated with recurrence-free survival of cancer patients. Here, CALCRL is linked to bone metastasis.